Sugi Predict

Sugi Predict / Targets / CDK13

CDK13

Cyclin-dependent kinase 13 · Q14004 · CDK13 on Sugi Atlas →

16,889 patent compounds predicted against CDK13, 11,813 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1164459 SCHEMBL1164459 0.55 9/20
SCHEMBL1413901 SCHEMBL1413901 0.49 4/20
SCHEMBL2918241 SCHEMBL2918241 0.43 3/20
SCHEMBL1820975 SCHEMBL1820975 0.43 3/20
SCHEMBL2921199 SCHEMBL2921199 0.42 3/20
SCHEMBL2028394 SCHEMBL2028394 0.39 3/20
Bms-345541 Bms-345541 (SCHEMBL118886) 1.00 2/20
SCHEMBL1487772 SCHEMBL1487772 0.53 2/20
SCHEMBL2814584 SCHEMBL2814584 0.52 2/20
SCHEMBL1720873 SCHEMBL1720873 0.50 2/20
SCHEMBL2820359 SCHEMBL2820359 0.49 2/20
SCHEMBL2814867 SCHEMBL2814867 0.48 2/20
SCHEMBL2815105 SCHEMBL2815105 0.48 2/20
SCHEMBL2816172 SCHEMBL2816172 0.48 2/20
SCHEMBL2816322 SCHEMBL2816322 0.48 2/20
SCHEMBL2817052 SCHEMBL2817052 0.48 2/20
SCHEMBL2817829 SCHEMBL2817829 0.48 2/20
SCHEMBL2816936 SCHEMBL2816936 0.48 2/20
SCHEMBL2813901 SCHEMBL2813901 0.47 2/20
SCHEMBL2177541 SCHEMBL2177541 0.46 2/20

Clinical trials — most relevant to CDK13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) PHASE3ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation PHASE2ACTIVE_NOT_RECRUITING
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer PHASE2COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors PHASE1/PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Palbociclib and Cetuximab in Metastatic Colorectal Cancer PHASE2COMPLETED
RP-6306 in Patients With Advanced Cancer PHASE2COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors PHASE1RECRUITING
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors PHASE1COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets PHASE1UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
The SONImage Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK13 binder may also engage these)

ProteinNameSimilarity
E1BB52 — 1.000 E1BB52 →
Q69ZA1 — 1.000 Q69ZA1 →
Q14AX6 — 0.997 Q14AX6 →
Q3MJK5 — 0.995 Q3MJK5 →
E1BB50 — 0.992 E1BB50 →
B5DE93 — 0.991 B5DE93 →
Q80TZ9 — 0.990 Q80TZ9 →
Q63553 — 0.989 Q63553 →
CDK12 Cyclin-dependent kinase 12 0.989 landscape →
P97868 — 0.988 P97868 →
Q9H329 — 0.988 Q9H329 →
Q8K3A9 — 0.988 Q8K3A9 →
Q9VP22 — 0.988 Q9VP22 →
Q3UHD9 — 0.988 Q3UHD9 →
Q62901 — 0.987 Q62901 →
CDKL5 Cyclin-dependent kinase-like 5 0.987 landscape →
Q06831 — 0.987 Q06831 →
MINK1 Misshapen-like kinase 1 0.987 landscape →
P48435 — 0.987 P48435 →
Q9JM52 — 0.987 Q9JM52 →
Q99490 — 0.987 Q99490 →
Q9Z0Y7 — 0.987 Q9Z0Y7 →
P30415 — 0.987 P30415 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.987 landscape →
Q24595 — 0.987 Q24595 →
Q9P2R6 — 0.987 Q9P2R6 →
Q5TZ18 — 0.987 Q5TZ18 →
Q8VDU5 — 0.986 Q8VDU5 →
Q9Z1N7 — 0.986 Q9Z1N7 →
D2H526 — 0.986 D2H526 →